EGFR and neoplasm: Sym004 has shown clinically meaningful rates of PR (13%) and minor tumor regression (44%) of target lesions in the Phase I trial (NCT01117428) in patients with KRAS WT mCRC and acquired resistance to anti-EGFR inhibitors (Dienstmann et al., 2015).